CS2 & CS12: Motor function results

SPINRAZA® improves and stabilises motor function in later-onset SMA1

  • SPINRAZA®-treated patients with later-onset (Type II/III) SMA maintained and increased motor function over 3 years1
  • In Type II patients, no plateau was observed1

Change in HFMSE score1

Scheme
Scheme
Banner
Banner

Lauren
age 20 years*
Later-onset (Type III) SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.